MedTrace Logo

Bone Mineral Density and Periodontal Status in Patients on Antiepileptic Drug

NCT04262999 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 140

Last updated 2020-02-10

No results posted yet for this study

Summary

Assessment of bone mineral density and periodontal parameters in patients with epilepsy. Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on monotherapy, combination therapy, and systemically healthy individuals.Comparative evaluation of periodontal parameters in all the patients who are on monotherapy and combination therapy and in systemically healthy individuals.

Conditions

  • Alveolar Bone Loss

Interventions

OTHER

effect of sodium valproate on alveolar bone level

Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on sodium valproate drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on sodium valproate drug therapy.

OTHER

effect of levetiracetam on alveolar bone level

Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on levetiracetam drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on levetiracetam drug therapy.

OTHER

effect of sodium valproate+levetiracetam on alveolar bone level

Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on sodium valproate+levetiracetam drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on sodium valproate+ levetiracetam drug therapy.

OTHER

control group

Control group individuals will be systemically healthy.

Sponsors & Collaborators

  • Postgraduate Institute of Dental Sciences Rohtak

    lead OTHER

Principal Investigators

  • Swati Jaglan, MDS · Post Graduate Institute of Dental Sciences,Rohtak

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2021-04-30
Completion
2021-04-30

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04262999 on ClinicalTrials.gov